Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 5.3.99.5 - thromboxane-A synthase and Organism(s) Homo sapiens

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
A selective thromboxane synthetase inhibitor, OKY-046, fails to improve blood rheology in endotoxin-shocked rabbits.
Acidosis, Respiratory
Differential responses of porcine anterior spinal and middle cerebral arteries to carbon dioxide and pH.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Acute Kidney Injury
Nephrotoxicity of cyclosporine: the role of platelet-activating factor and thromboxane.
The protective effects of Iloprost and thromboxane synthetase inhibitor, UK 38485, against glycerol--induced acute renal failure in rats.
Acute Lung Injury
Differential effects of cyclo-oxygenase and thromboxane synthetase inhibition on ventilation-perfusion relationships in acid aspiration-induced acute lung injury.
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep.
Ketoconazole and pulmonary failure after esophagectomy: a prospective clinical trial.
Mediators of lung injury in mice following systemic activation of complement.
Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury.
Adenocarcinoma
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
The effect of prostaglandin modulators on prostate tumor growth and metastasis.
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Adenocarcinoma of Lung
Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase.
Albuminuria
Diverse associations between oxidative stress and thromboxane A2 in hypertensive glomerular injury.
Anaphylaxis
N-(heterocyclic alkyl)pyrido[2,1-b]quinazoline-8-carboxamides as orally active antiallergy agents.
Aneurysm
Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report.
Angina Pectoris
Selective thromboxane A2 synthetase inhibition in vasospastic angina pectoris.
[Treatment of angina pectoris. New perspectives]
Angina, Stable
Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris.
Arrhythmias, Cardiac
Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
Arterial Occlusive Diseases
11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period.
The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
Arthritis, Experimental
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Asthma
A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients.
Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients.
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
Effect of OKY-046, a new thromboxane A2 synthetase inhibitor, on experimental asthma in guinea pigs.
Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Genome-wide interaction study reveals age-dependent determinants of responsiveness to inhaled corticosteroids in individuals with asthma.
Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma.
The role of thromboxane in allergen-induced asthmatic responses.
Therapeutic potential of thromboxane inhibitors in asthma.
Thromboxane A2 and related prostaglandins in airways.
Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.
[Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects]
[Thromboxane A2 synthetase inhibitor in asthma therapy]
Astrocytoma
Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase.
Atherosclerosis
Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population.
BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Contribution of arachidonic acid metabolites to atherosclerosis.
Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis.
Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: Correlation with plaque composition.
The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats.
Thromboxane A synthase 1 gene expression and promotor haplotypes are associated with risk of large artery-atherosclerosis stroke in Iranian population.
Thromboxane synthase expression and thromboxane A(2) production in the atherosclerotic lesion.
[Treatment of angina pectoris. New perspectives]
Blood Platelet Disorders
[Genetic defects of prostaglandin and thromboxane synthesis]
Bone Resorption
The effect of imidazole-analogues on bone resorption in vitro: a suggested role for thromboxane A2.
Bradycardia
Direct and indirect effects of leukotriene D4 on the lungs of unanesthetized sheep.
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Brain Ischemia
Effect of thromboxane synthetase inhibitor on cerebral circulation and metabolism during experimental cerebral ischemia in spontaneously hypertensive rats.
Inhibition of thromboxane A2 production does not improve post-ischemic brain hypoperfusion in the dog.
Role of platelets as a factor aggravating cerebral ischemia.
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats.
[Protective effect of thromboxane A2 synthetase inhibitor (trapidil) on acutely-induced cerebral ischemia]
Breast Neoplasms
Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.
Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets.
Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer.
Inhibiting breast cancer by targeting the thromboxane A2 pathway.
Bronchial Spasm
Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3- (1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm.
Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.
Bronchiectasis
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Bronchitis, Chronic
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma.
Effect of thromboxane A2 synthetase inhibitor, OKY-046, on sputum in chronic bronchitis and diffuse panbronchiolitis.
[Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects]
Calcinosis
The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition.
Carcinogenesis
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells.
Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets.
Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells.
Carcinoma
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase.
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation.
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Carcinoma, Lewis Lung
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Carcinoma, Non-Small-Cell Lung
18?-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer.
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells.
Carcinoma, Renal Cell
Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase.
Carcinoma, Squamous Cell
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Carcinoma, Transitional Cell
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Cardiomyopathies
A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Cardiovascular Diseases
Genomic structure and polymorphism of the human thromboxane synthase-encoding gene.
Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease.
Cerebral Infarction
Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population.
Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits.
Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats.
[Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery]
Cerebrovascular Disorders
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Testosterone treatment increases thromboxane function in rat cerebral arteries.
The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients.
[Treatment of occlusive cerebrovascular disease with a selective thromboxane A2 synthetase inhibitor]
Cholestasis
The protective effect of thromboxane synthetase inhibitor UK 38485 against bile duct ligation induced liver injury.
Colitis
Prostaglandin regulation of colonic blood flow in rabbit colitis.
Resolution of Cox mediated inflammation by Se supplementation in mouse experimental model of colitis.
Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis.
Colitis, Ulcerative
Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
Thromboxane synthase immunohistochemistry in inflammatory bowel disease.
Colorectal Neoplasms
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
Congenital Abnormalities
Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation.
Possible congenital defect in platelet thromboxane synthetase.
Coronary Artery Disease
Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise.
Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.
[Pathogenetic and therapeutic significance of the angioprotective systems in patients with coronary arteriosclerosis]
Coronary Disease
Effects of dazoxiben on exercise performance in chronic stable angina.
Coronary Occlusion
Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs.
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion.
Coronary Stenosis
Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis.
Coronary Thrombosis
Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog.
Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs.
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis.
Cough
Involvement of thromboxane A(2) in airway mucous cells in asthma-related cough.
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
[Chronic persistent coughing successfully treated with ozagrel]
Crohn Disease
Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.
Death, Sudden, Cardiac
Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane.
Dementia
Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia.
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Dementia, Vascular
Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia.
Dermatitis
Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice.
Diabetes Mellitus, Experimental
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Diabetes Mellitus, Type 2
Prostaglandins and diabetic nephropathy.
Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy.
Diabetic Nephropathies
A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy.
Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy.
Diabetic Retinopathy
Effects of high glucose concentration and a thromboxane synthase inhibitor on the production of thromboxane A2 and prostaglandin I2 and E2 by retinal endothelial cells.
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Specific thromboxane synthetase inhibition and retinopathy in insulin-dependent diabetics.
Disseminated Intravascular Coagulation
Role of activated platelets in endotoxin-induced DIC in rats.
Dyslipidemias
The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome.
Up-regulation of thromboxane A(2) impairs cerebrovascular eNOS function in aging atherosclerotic mice.
Embolic Stroke
[The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction]
Embolism, Air
Effect of thromboxane synthetase inhibitors (OKY-046, OKY-1580) on experimentally induced air embolism in anesthetized dogs.
Endometriosis
Anti-platelet therapy is efficacious in treating endometriosis induced in mouse.
Endotoxemia
Dazoxiben in human sepsis and adult respiratory distress syndrome.
Dose-dependent effects of a pyridoquinazoline thromboxane synthetase inhibitor on arachidonic acid metabolites and hemodynamics during E. coli endotoxemia in anesthetized sheep.
Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia.
Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor.
Protective effects of a thromboxane synthetase inhibitor and continuous arteriovenous hemofiltration in rat endotoxic shock.
The effect of thromboxane synthetase inhibition on cardiopulmonary function during endotoxemia in sheep.
Thromboxane synthase inhibition and cardiopulmonary function during endotoxemia in sheep.
Eosinophilia
Effects of a thromboxane synthase inhibitor (CS-518) on the eosinophil-dependent late asthmatic response and airway hyperresponsiveness in guinea pigs.
Epiretinal Membrane
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Erectile Dysfunction
Possible utility of a thromboxane synthetase inhibitor in preventing penile vascular changes and impotence during aging.
Erythema
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Essential Hypertension
Role of thromboxane A2 in the hypotensive effect of captopril in essential hypertension.
Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
Familial Primary Pulmonary Hypertension
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Thromboxane synthetase inhibition in primary pulmonary hypertension.
Feline Infectious Peritonitis
Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats.
Fetal Growth Retardation
Effects of a thromboxane synthetase inhibitor (OKY-046) in an ischemia-reperfusion model of intrauterine growth retardation in Sprague-Dawley rats.
Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy.
Fibrosarcoma
Dissociation between thromboxane generation and metastatic potential in cells from a murine fibrosarcoma. Studies with a selective thromboxane synthase inhibitor.
Glioblastoma
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.
Glioma
Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase.
Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells.
Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation.
Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.
Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells.
Thromboxane synthase regulates the migratory phenotype of human glioma cells.
Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.
Glomerulonephritis
Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat.
Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
Effects of a selective thromboxane A2 synthetase inhibitor on immune complex glomerulonephritis.
Effects of a specific thromboxane synthetase inhibitor on development of experimental Dirofilaria immitis immune complex glomerulonephritis in the dog.
Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs.
Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
[Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis]
Glomerulonephritis, IGA
Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy.
Glomerulonephritis, Membranoproliferative
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
Glomerulonephritis, Membranous
Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.
Gout
[Association of single nucleotide polymorphisms of cytochrome P450 gene with susceptibility to gout in ethnic Han males from coastal regions of Shandong province].
Heart Arrest
[Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151]
Heart Diseases
Thromboxane synthase inhibition in patients with atherosclerotic heart disease.
Heart Failure
[Right heart function and endotoxemia in animals]
Hepatitis A
Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Hepatitis C
Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Hepatitis, Alcoholic
Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
Hernias, Diaphragmatic, Congenital
Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: modification of the pulmonary vasoactive profile.
Hydronephrosis
Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989.
Hyperinsulinism
A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity.
Hypersensitivity
A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients.
Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients.
Effect of thromboxane A2 synthetase inhibitor on immediate-type hypersensitivity reactions.
Hypertension
Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension.
Attenuation of the development of hypertension in spontaneously hypertensive rats by the thromboxane synthetase inhibitor, 4'-(imidazol-1-yl) acetophenone.
Chronic thromboxane synthase inhibition prevents fructose-induced hypertension.
Contrasting effect of thromboxane synthase inhibitors and a thromboxane receptor antagonist on the development of angiotensin II-salt-induced hypertension in rats.
Cyclooxygenase pathway mediates lung injury induced by phorbol and platelets.
Cyclosporine-induced hypertension in sheep. The role of thromboxanes.
Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2 synthetase inhibitor.
Effects of continuous ingestion of hesperidin and glucosyl hesperidin on vascular gene expression in spontaneously hypertensive rats.
Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat.
Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.
Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension.
Identification of Hub Genes Associated with Hypertension and Their Interaction with miRNA Based on Weighted Gene Coexpression Network Analysis (WGCNA) Analysis.
Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy.
Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension.
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension.
Pharmacokinetics of furegrelate after oral administration to normal humans.
Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia.
Thromboxane A2 and development of genetic hypertension in the Lyon rat strain.
Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats.
Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.
Thromboxane synthetase inhibitor UK38,485 lowers blood pressure in the adult spontaneously hypertensive rat.
[Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension]
Hypertension, Pregnancy-Induced
Beneficial effects of U-63,557A, a thromboxane synthetase inhibitor, in an ovine model of pregnancy-induced hypertension.
Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension.
Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension.
Erythrocyte morphologic features and serum chemistry studies in ovine pregnancy-induced hypertension treated with thromboxane synthetase inhibitors.
Preliminary observations on treatment of pregnancy-induced hypertension with a thromboxane synthetase inhibitor.
Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension.
Thromboxane synthetase inhibition in pregnancy-induced hypertension.
Thromboxane synthetase inhibition produces maternal and fetal vasodilation during ovine pregnancy-induced hypertension: a Doppler flow velocimetric study.
Hypertension, Pulmonary
A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.
Capsular type-specific polysaccharide partially inhibits group B Streptococcus-induced pulmonary hypertension.
Dazoxiben in human sepsis and adult respiratory distress syndrome.
Effect of blood and albumin on pulmonary hypertension and edema in perfused rabbit lungs.
Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery.
Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension.
Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: modification of the pulmonary vasoactive profile.
Hyperbaric oxygen toxicity: role of thromboxane.
Impact of prostaglandin and thromboxane synthesis blockade on disposition of group B streptococcus in lung and liver of intact piglet.
In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade.
Intrinsic microbicidal activity and pulmonary hypertension in isolated newborn piglet lungs.
Lipoxygenase and cyclooxygenase blockade by BW755C does not prevent the secondary phase of septic pulmonary hypertension.
Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury.
Protein complex formation with heat shock protein 90 in chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Selective inhibition of thromboxane synthetase reduces group-B-beta-hemolytic-streptococci-induced pulmonary hypertension in piglets.
Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets.
Thromboxane-associated pulmonary hypertension during three types of gram-positive bacteremia in piglets.
Hypoparathyroidism
[Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism]
Hypotension
Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue.
Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs.
Putative mechanism of hypotensive action of platelet-activating factor in dogs.
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Thromboxane synthase inhibition enhances action of converting enzyme inhibitors.
Infarction, Middle Cerebral Artery
Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
Infections
Indomethacin in vivo increases the sensitivity to Listeria infection in mice. A possible role for macrophage thromboxane A2 synthesis.
Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes.
Inflammatory Bowel Diseases
Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors.
Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.
Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease.
Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers.
Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease.
Thromboxane synthase immunohistochemistry in inflammatory bowel disease.
Insulin Resistance
Chronic thromboxane synthase inhibition prevents fructose-induced hypertension.
Intracranial Aneurysm
Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study.
Intracranial Embolism
Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits.
Intracranial Thrombosis
Clinical study on effect of thromboxane A2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis.
[Antithrombotic therapy in cerebral infarction]
Iron Overload
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Ischemic Stroke
Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population.
Cinnamate Hybrids: A Unique Family of Compounds with Multiple Biological Activities.
Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction.
Variants in COX-2, PTGIS, and TBXAS1 Are Associated with Carotid Artery or Intracranial Arterial Stenosis and Neurologic Deterioration in Ischemic Stroke Patients.
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
[Strategy for circulatory disturbance]
[The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction]
Kidney Diseases
Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease.
The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300.
Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.
Leukemia
Differentiation-associated expression of prostaglandin H and thromboxane A synthases in monocytoid leukemia cell lines.
Manipulation of thromboxane synthesis by novel 26,27-dialkyl analogues of 1 alpha,25-dihydroxyvitamin D3 in human promyelocytic leukemia (HL-60) cells.
Leukemia, Erythroblastic, Acute
Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells.
Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNAs in human erythroleukemia cells by phorbol ester.
Liver Diseases
Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis.
Liver Diseases, Alcoholic
Alterations in thromboxane synthase and thromboxane A2 receptors in experimental alcoholic liver disease.
Lung Injury
Effects of OKY-046, a selective thromboxane synthetase inhibitor, on endotoxin-induced lung injury in unanesthetized sheep.
Effects of thromboxane synthase inhibition on air emboli lung injury in sheep.
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep.
Inhibition of cyclooxygenase metabolite production attenuates ischemia-reperfusion lung injury.
Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs.
Lung Neoplasms
18?-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer.
4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor.
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27.
Thromboxane A2 receptor ? promotes tumor growth through an autoregulatory feedback pathway.
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB.
Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells.
Lupus Erythematosus, Systemic
Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE.
Lupus Nephritis
Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
Lymphoma, Non-Hodgkin
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Malaria, Cerebral
L-arginine supplementation and thromboxane synthase inhibition increases cerebral blood flow in experimental cerebral malaria.
Melanoma
Ketoconazole: a thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma.
Memory Disorders
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Mesenteric Ischemia
The effects of prostacyclin analogue ZK 36374 and thromboxane synthetase inhibitor UK 38485 on mesenteric ischemia in guinea pigs.
Mesothelioma
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Mesothelioma, Malignant
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
Migraine Disorders
Thromboxane synthetase inhibition: potential therapy in migraine.
Mucocutaneous Lymph Node Syndrome
Implication of thromboxane in the pathogenesis of Kawasaki disease and a suggestion for using novel thromboxane synthetase inhibitors in its treatment.
Myocardial Infarction
Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction.
BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046).
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
Role of a genetic variation in the promoter of human thromboxane synthase gene in myocardial infarction.
The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models.
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
[Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang].
[Association of the Pro1770Leu polymorphism in CYP5A1 gene with myocardial infarction in Uigur population of Xinjiang.]
Myocardial Ischemia
A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia.
Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
Improved lactate extraction in dogs with coronary artery ligation following administration of a thromboxane synthetase inhibitor.
Inhibition of thromboxane synthetase by the imidazole derivative 3-(1H-imidazol-1-yl-methyl)-2-methyl-1H-indole-1-propanoic acid as a novel therapeutic approach to experimental myocardial ischemia.
Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
Salutary actions of thromboxane synthetase inhibition during global myocardial ischemia.
Selective thromboxane synthetase inhibitor and ischemic heart disease.
The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia.
Myocardial Stunning
Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart.
Neonatal Sepsis
Effects of the thromboxane synthetase inhibitor, dazmegrel (UK 38,485), on pulmonary gas exchange and hemodynamics in neonatal sepsis.
Neoplasm Metastasis
Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells.
Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).
Eicosanoids and metastasis: experimental aspects in Lewis lung carcinoma.
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Thromboxane synthase and organ preference for metastases.
Neoplasms
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells.
Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells.
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Apigenin inhibits tumor necrosis factor alpha plus high glucose induced-LOX-1 expression in human endothelial cells.
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases.
Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).
Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.
Effects of systemic complement activation and neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer cells in mouse lungs.
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep.
Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis.
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer.
G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis.
Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Phenotypic properties of cultured tumor cells: integrin alpha IIb beta 3 expression, tumor-cell-induced platelet aggregation, and tumor-cell adhesion to endothelium as important parameters of experimental metastasis.
Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia.
Role of postaglandins in metastatic dissemination of cancer. Minireview on cancer research.
Role of prostaglandins in metastatic dissemination of cancer. Minireview on cancer research.
The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy.
The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat.
The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.
Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.
Thromboxane A2 receptor ? promotes tumor growth through an autoregulatory feedback pathway.
Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho.
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB.
Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
Nephritis
Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats.
Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase.
Rabbit nephrotoxic nephritis: effect of a thromboxane synthetase inhibitor on evolution and prostaglandin excretion.
The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.
The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions.
Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit.
Nephrotic Syndrome
Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome.
The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome.
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
[The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation]
Neuroinflammatory Diseases
Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia.
Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia.
Obesity
A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity.
Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression.
Pancreatic Neoplasms
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints.
Pancytopenia
Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency.
Peripheral Arterial Disease
Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
Peripheral Vascular Diseases
Initial impressions of dazoxiben in the treatment of the ischaemic limb.
Peritonitis
Acute renal failure and sepsis: therapeutic approaches.
Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats.
Gentamicin and indomethacin in the treatment of septic shock: effects on prostacyclin and thromboxane A2 production.
Pituitary Neoplasms
Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.
Pleurisy
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Pre-Eclampsia
Antithromboxane drug in the treatment of preeclampsia.
Effects of a thromboxane synthetase inhibitor on platelet function; possible risks of use in pregnancy.
Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension.
Effects of thromboxane synthetase inhibitor (OKY-046) on placental blood flow, placental weight and fetal weight in normotensive and spontaneously hypertensive rats.
Eicosanoid biosynthetic enzymes in placental and decidual tissues from preeclamptic pregnancies: increased expression of thromboxane-A2 synthase gene.
Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia.
The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report.
Thromboxane synthetase inhibition as a new therapy for preeclampsia: animal and human studies minireview.
Proteinuria
Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives.
Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE.
Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor.
[Effects of a selective thromboxane A2 synthetase inhibitor, OKY-046, on proteinuria of aminonucleoside nephrotic rats]
[The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation]
Pulmonary Arterial Hypertension
Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.
Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension.
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension.
Pulmonary Edema
Alpha-thrombin-induced pulmonary vasoconstriction.
Pulmonary Embolism
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Effect of OKY 046, a thromboxane synthase inhibitor, on lung vascular permeability after pulmonary embolism in sheep.
Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat.
Pulmonary Eosinophilia
Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs.
Pulmonary Fibrosis
Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice.
Renal Insufficiency
Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.
Reperfusion Injury
Effects of thromboxane A2 synthetase inhibitor (CV-4151) on reperfused skeletal muscle in rats.
Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation.
Reduction of reperfusion injury in rat skeletal muscle following administration of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
The effects of thromboxane synthase inhibition on reperfusion injury and endothelin-1,2 levels in allograft kidney transplantation in rats.
Respiratory Distress Syndrome
A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome.
Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome.
Role of arachidonic acid metabolites in oleic acid induced pulmonary injury in a canine model. Effect of ketoconazole (thromboxane synthetase inhibitor).
Respiratory Insufficiency
[Protective effect of a thromboxane synthetase inhibitor, OKY-046, in patients with acute respiratory failure]
[The effect of cyclooxygenase and thromboxane synthetase inhibition on oxygen metabolism in canine acute respiratory failure]
Scleroderma, Systemic
Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis.
Seizures
The effect of inhibiting brain thromboxane biosynthesis on pentylenetetrazole-induced seizure threshold.
Sepsis
Effects of a specific thromboxane synthetase inhibitor in equine endotoxaemia.
Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension.
Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
The protective effect of thromboxane synthetase inhibition on renal function in systemic sepsis.
Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model.
Thromboxane synthetase inhibitors in septic shock.
Shock, Septic
A selective thromboxane synthetase inhibitor, OKY-046, fails to improve blood rheology in endotoxin-shocked rabbits.
Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia.
Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes.
Protection of myocardial function during endotoxin shock by ibuprofen.
Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits.
Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock.
Thromboxane synthetase inhibitors in septic shock.
Small Cell Lung Carcinoma
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Spasm
Intracoronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholine-induced coronary spasm.
Roles of thromboxanes in gastrointestinal physiopathology.
Stroke
Effects of Furegrelate (Upjohn 63557A) on patency and platelet deposition after canine carotid endarterectomy.
Interactions among Variants in Eicosanoid Genes Increase Risk of Atherothrombotic Stroke in Chinese Populations.
Interference of levamisole with cerebral edema.
N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production.
Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase.
The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients.
Thromboxane A synthase 1 gene expression and promotor haplotypes are associated with risk of large artery-atherosclerosis stroke in Iranian population.
Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats.
Thromboxane A2 synthetase inhibitor plus low dose aspirin : can it be a salvage treatment in acute stroke beyond thrombolytic time window.
[Strategy for circulatory disturbance]
Stroke, Lacunar
[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]
Subarachnoid Hemorrhage
Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage.
Effect of diltiazem and thromboxane A2 synthetase inhibitor (OKY-046) on vessels following experimental subarachnoid hemorrhage.
Effect of selective inhibitor of thromboxane A2 synthetase on cerebral vasospasm after early surgery.
Effects of subarachnoid hemorrhage and a thromboxane A2 synthetase inhibitor on intracranial prostaglandins.
Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage.
Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581.
[Experimental study on the prevention of vasospasm following subarachnoid hemorrhage by a thromboxane A2 synthetase inhibitor, OKY-046]
[Prevention of vasospasm following subarachnoid hemorrhage using a thromboxane A2 synthetase inhibitor (OKY-046)--clinical study among multiple institutions]
Tachycardia, Ventricular
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Thromboxane A2 does not contribute to arrhythmogenesis during evolving canine myocardial infarction.
Thrombocytopenia
CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig.
Platelet-lung in vivo interactions: an artifact of a multi-purpose model?
Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.
Thromboembolism
Cerebral platelet thromboembolism and thromboxane synthetase inhibition.
Mechanism of action of dipyridamole.
Thrombosis
8th Seah Cheng Siang Memorial Lecture: new antithrombotic agents.
A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbits.
Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01).
Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
Carrageenin-induced thrombosis in the rat and mouse as a test model of substances influencing thrombosis.
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.
Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
Effect of dazoxiben on arterial graft thrombosis in the baboon.
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Exchange of cyclooxygenase dependent metabolites between vessel wall and platelets in arterial thrombosis.
Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis.
Fibrin, red cell and platelet interactions in an experimental model of thrombosis.
Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
Microsurgical carotid endarterectomy in rats.
Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP.
Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants.
Pharmacokinetics of furegrelate after oral administration to normal humans.
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation.
Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo.
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Testosterone treatment increases thromboxane function in rat cerebral arteries.
The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.
The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding.
The effect of platelet inhibitory therapy on graft thromboresistance.
Thrombotic Microangiopathies
The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300.
thromboxane-a synthase deficiency
Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency.
Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism.
Hereditary bleeding disorder due to a primary defect in platelet release reaction.
Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder.
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
Thromboxane synthase deficiency improves insulin action and attenuates adipose tissue fibrosis.
[Deficiencies of the prostaglandin system: III. A partial thromboxane synthetase defect]
[Platelet thromboxane synthase deficiency]
Thyroid Cancer, Papillary
Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.
Toxemia
Fetal and maternal response to intravenous infusion of a thromboxane synthetase inhibitor.
Ureteral Obstruction
Effect of thromboxane inhibition on renal blood flow in dogs with complete unilateral ureteral obstruction.
Urinary Bladder Neoplasms
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring.
Vascular Diseases
Thromboxane A(2) increases endothelial permeability through upregulation of interleukin-8.
Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells.
Vascular System Injuries
Genetic Depletion of Thromboxane A2/Thromboxane-Prostanoid Receptor Signalling Prevents Microvascular Dysfunction in Ischaemia/Reperfusion Injury.
Vasospasm, Intracranial
Beneficial effect of OKY-046, a selective thromboxane A2 synthetase inhibitor, on experimental cerebral vasospasm.
Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study.
Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage.
Effect of selective inhibitor of thromboxane A2 synthetase on cerebral vasospasm after early surgery.
Effect of selective inhibitor of thromboxane A2 synthetase on experimental cerebral vasospasm.
Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm.
Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage.
Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581.
Prevention of cerebral vasospasm with OKY-046 an imidazole derivative and a thromboxane synthetase inhibitor. A preliminary co-operative clinical study.
Prostacyclin and thromboxane in cerebral vasospasm II: Effects of thromboxane synthetase inhibitor (OKY-1581) on experimentally-induced cerebral vasospasm.
Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report.
Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm.
Ventricular Fibrillation
Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias.
Comments on "The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs".
Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death.
The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs.